Current epidemiology and growing resistance of gram-negative pathogens
- PMID: 22707882
- PMCID: PMC3372794
- DOI: 10.3904/kjim.2012.27.2.128
Current epidemiology and growing resistance of gram-negative pathogens
Abstract
In the 1980s, gram-negative pathogens appeared to have been beaten by oxyimino-cephalosporins, carbapenems, and fluoroquinolones. Yet these pathogens have fought back, aided by their membrane organization, which promotes the exclusion and efflux of antibiotics, and by a remarkable propensity to recruit, transfer, and modify the expression of resistance genes, including those for extended-spectrum β-lactamases (ESBLs), carbapenemases, aminoglycoside-blocking 16S rRNA methylases, and even a quinolone-modifying variant of an aminoglycoside-modifying enzyme. Gram-negative isolates--both fermenters and non-fermenters--susceptible only to colistin and, more variably, fosfomycin and tigecycline, are encountered with increasing frequency, including in Korea. Some ESBLs and carbapenemases have become associated with strains that have great epidemic potential, spreading across countries and continents; examples include Escherichia coli sequence type (ST)131 with CTX-M-15 ESBL and Klebsiella pneumoniae ST258 with KPC carbapenemases. Both of these high-risk lineages have reached Korea. In other cases, notably New Delhi Metallo carbapenemase, the relevant gene is carried by promiscuous plasmids that readily transfer among strains and species. Unless antibiotic stewardship is reinforced, microbiological diagnosis accelerated, and antibiotic development reinvigorated, there is a real prospect that the antibiotic revolution of the 20th century will crumble.
Keywords: Acinetobacter; Carbapenemase; Enterobacteriaceae; Pseudomonas; β-lactamase.
Conflict of interest statement
No potential conflict of interest relevant to this article was reported.
Figures
References
-
- Boucher HW, Talbot GH, Bradley JS, et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis. 2009;48:1–12. - PubMed
-
- Holmes NE, Howden BP. The rise of antimicrobial resistance: a clear and present danger. Expert Rev Anti Infect Ther. 2011;9:645–648. - PubMed
-
- Livermore DM British Society for Antimicrobial Chemotherapy Working Party on The Urgent Need: Regenerating Antibacterial Drug Discovery and Development. Discovery research: the scientific challenge of finding new antibiotics. J Antimicrob Chemother. 2011;66:1941–1944. - PubMed
-
- Payne DJ, Gwynn MN, Holmes DJ, Pompliano DL. Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat Rev Drug Discov. 2007;6:29–40. - PubMed
-
- Finch R BSAC Working Party on the Urgent Need: Regenerating Antibacterial Drug Discovery and Development. Regulatory opportunities to encourage technology solutions to antibacterial drug resistance. J Antimicrob Chemother. 2011;66:1945–1947. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical